Pro-inflammatory mediators and oxidative stress in liver transplantation patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12613000075785

Enrollment

Registered

2013-01-21

Start date

2009-12-07

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Single fasting blood samples will be collected from each study participant for analysis of pro-inflammatory mediators and oxidative stress. At the time of blood sample collection, isolated neutrophils will be for measurement of superoxide production and elastase activity. Results of pro-inflammatory mediators and oxidative stress obtained from liver tranaplantation recepients will be statistically compared to those obtained from healthy controls using analysis of variance (ANOVA).

Interventions

We have attempted to analyze the blood samples for measurement of pro-inflammatory mediators and oxidative stress before liver tranaplantation in the operation room. The approximate duration that measurements take in each patient is 5 minutes only. In addition, single blood sample is taken from vein.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Participant is >=18 years of age at the time of informed consent. 2. Participant is a male or non-pregnant, non-lactating female. 3. Participant is either: i. a patient diagnosed with end stage liver failure by a physician according to the standard diagnostic criteria; or ii. a healthy subject with no clinically significant conditions. 4. Participant is aware of the study procedures and the risks involved and voluntarily agrees to participate by providing written informed consent.

Exclusion criteria

1. Patients with sepsis, shock, hepatoencephalopathy, hepatorenal syndrome, severe pulmonary hypertension (>35mmHg), or antioxidants taking recently, as well as patients with massive ascites or pleural effusion were excluded. 2. Participant has a history or current evidence of any condition, therapy or laboratory abnormality that, in the opinion of the investigator, might affect the results of the study or may not be in the best interest of the individual to participate. 3. Participant has participated in a clinical trial within 2 months of study participation that, in the opinion of the investigator, might affect the results of the study or may not be in the best interest of the individual to participate.

Outcome results